Table 2.
Progression-free survivala | Overall survivala | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||||
Unadjusted model | Adjusted modelb | Unadjusted model | Adjusted modelb | |||||||||
|
|
|
|
|||||||||
HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
c-MYC amplificationc | ||||||||||||
≥ 2 c-MYC/CEP8 copies | ||||||||||||
No | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Yes | 1.03 | 0.65–1.64 | 0.884 | 1.03 | 0.57–1.85 | 0.922 | 1.08 | 0.68–1.72 | 0.745 | 1.01 | 0.56–1.80 | 0.982 |
c-MYC amplificationd | ||||||||||||
≥ 1.5 c-MYC/CEP8 copies | ||||||||||||
No | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Yes | 1.37 | 0.89–2.10 | 0.151 | 1.06 | 0.63–1.77 | 0.837 | 1.14 | 0.74–1.76 | 0.555 | 1.03 | 0.60–1.75 | 0.920 |
Polysomy for chromosome 8e | ||||||||||||
≥ 4 CEP8 copies | ||||||||||||
No | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
Yes | 0.99 | 0.62–1.59 | 0.982 | 1.07 | 0.57–2.02 | 0.823 | 1.08 | 0.67–1.74 | 0.747 | 1.04 | 0.54–1.99 | 0.916 |
Estimated hazard ratio (HR), 95% confidence interval (95% CI).
Cox regression analysis for modeling the relative risk of disease progression or death; p-values are based on the Wald test.
Models were adjusted for patient age at enrollment in years, and stratified by tumor stage (III vs. IV), histologic subtype (clear cell or mucinous vs. other histologic subtypes), tumor grade (well differentiated vs. moderately differentiated vs. poorly differentiated), measurable disease status (non-measurable vs. measurable), and treatment regimen (cyclophosphamide + cisplatin vs. paclitaxel + cisplatin).
c-MYC amplification was categorized as ‘No’ when tumors had <2 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥2 copies of c-MYC/CEP8 per cell.
c-MYC amplification was categorized as ‘No’ when tumors had <1.5 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥1.5 copies of c-MYC/CEP8 per cell.
Polysomy for chromosome 8 was categorized as ‘No’ when tumors had <4 copies of CEP8 per cell or ‘Yes’ when tumors had ≥4 copies of CEP8 per cell.